Dietary intake of inulin-type fructans in active and inactive Crohn’s disease and healthy controls: a case-control study

Anderson, Jacqueline L, Hedin, Charlotte R, Benjamin, Jane L, Koutsoumpas, Andreas, Ng, Siew C, Hart, Ailsa L, Forbes, Alastair ORCID: https://orcid.org/0000-0001-7416-9843, Stagg, Andrew J, Lindsay, James O and Whelan, Kevin (2015) Dietary intake of inulin-type fructans in active and inactive Crohn’s disease and healthy controls: a case-control study. Journal of Crohn's & Colitis, 9 (11). ISSN 1873-9946

[thumbnail of whelan fructans Submission%201]
Preview
PDF (whelan fructans Submission%201) - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (324kB) | Preview

Abstract

Background and Aims: Prebiotic inulin-type fructans are widely consumed in the diet and may have contrasting effects in Crohn’s disease by stimulating gut microbiota and/or by generating functional gastrointestinal symptoms. The aim of this study was to measure fructan and oligofructose intakes in patients with active and inactive Crohn’s disease compared with healthy controls. Methods: Patients with active Crohn’s disease (n=98), inactive Crohn’s (n=99) and healthy controls (n=106) were recruited to a case-control study. Dietary intake of inulin-type fructans was measured using a specific food frequency questionnaire and was compared between the three groups and between patients with different disease phenotypes (Montreal classification). Associations between intakes and disease activity (Harvey Bradshaw Index, HBI) were also undertaken. Results: Patients with active Crohn’s disease had lower fructan intakes (median 2.9 g/d, IQR 1.8) than those with inactive Crohn’s (3.6 g/d, 2.1, P=0.036) or controls (3.9 g/d, 2.1, P=0.003) and lower oligofructose intakes (2.8 g/d, 1.8) than inactive Crohn’s (3.5 g/d, 2.2, P=0.048) or controls (3.8 g/d, 2.1, P=0.003). There were no differences in intakes related to disease site or behaviour. There were negative correlations between HBI wellbeing score and fructan intake (ρ=-0.154, P=0.03) and oligofructose intake (ρ=-0.156, P=0.028) and for the HBI abdominal pain score and fructan (ρ=-0.164, P=0.021) and oligofructose intake (ρ=-0.157, P=0.027). Conclusions: Patients with active Crohn’s disease consume lower quantities of fructans and oligofructose than their inactive counterparts and healthy controls. The impact of lower intakes of prebiotic fructans on gut microbiota are unknown and warrant further research.

Item Type: Article
Additional Information: © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com
Uncontrolled Keywords: inflammatory bowel disease,inulin,fructan,oligofructose,fructans,fodmaps
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology
Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine
Depositing User: Pure Connector
Date Deposited: 13 Nov 2015 12:00
Last Modified: 21 Oct 2022 01:06
URI: https://ueaeprints.uea.ac.uk/id/eprint/55182
DOI: 10.1093/ecco-jcc/jjv136

Downloads

Downloads per month over past year

Actions (login required)

View Item View Item